Orbimed Advisors LLC Arcutis Biotherapeutics, Inc. Transaction History

Orbimed Advisors LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	SELL	$10.23 - $17.14 $5.58 Million - $9.35 Million	-545,629 Reduced 22.18%	1,914,479 $21.1 Million
Q4 2022 Feb 14, 2023	SELL	$13.96 - $20.4 $4.74 Million - $6.93 Million	-339,892 Reduced 12.14%	2,460,108 $36.4 Million
Q3 2022 Nov 14, 2022	SELL	$17.85 - $26.95 $35.4 Million - $53.4 Million	-1,981,646 Reduced 41.44%	2,800,000 $53.5 Million
Q2 2022 Aug 15, 2022	SELL	$16.33 - $22.2 $21.1 Million - $28.7 Million	-1,292,204 Reduced 21.27%	4,781,646 $102 Million
Q4 2020 Feb 16, 2021	BUY	$17.82 - $31.73 $24.9 Million - $44.4 Million	1,400,000 Added 29.95%	6,073,850 $171 Million
Q1 2020 May 15, 2020	BUY	$18.5 - $36.9 $86.5 Million - $172 Million	4,673,850 New	4,673,850 $139 Million

196

130M

738K

82K

Ticker ARQT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 60,187,500
Market Cap $797M
Description
Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing A...

Get notified when there are updates to the investment portfolio of Orbimed Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Orbimed Advisors LLC with notifications on news.